HLA-A*24:02 tetramers move CMV-specific CD8⁺ T cell immunity from inference to direct quantification
HLA-A*24:02 tetramer
- Recent Advances
- Product Information
Recent Advances
HLA‑A*24:02 Tetramers Move CMV-Specific CD8⁺ T-Cell Immunity from Inference to Direct Quantification
Summary: Taking the HLA‑A*24:02 tetramer as its main thread, this article successively reviews its genetic basis, the identification process of the CMV pp65-derived QYDPVAALF epitope it presents, the molecular principles of tetramer technology, and its application value in transplant immune monitoring, providing researchers engaged in infection immunology and tumor immunology with a clear methodological reference.
I. HLA‑A*24:02 Is a Widely Distributed HLA‑A Allele in East Asian Populations
Human leukocyte antigen (HLA)‑A*24:02 belongs to MHC class I molecules, and its distribution frequency in East Asian populations is significantly higher than in European and American populations, making it one of the most common HLA‑A alleles in Asian regions such as Japan and China. Because T cells can only recognize antigenic peptides presented by self-MHC molecules, differences in HLA allele distribution directly determine the research focus of virus-specific CD8⁺ T-cell responses in different populations. Therefore, establishing corresponding immune detection systems around HLA‑A*24:02 has clear necessity and practical significance for conducting antiviral immunity, tumor immunology, and adoptive cell therapy research in Chinese and East Asian populations.

II. QYDPVAALF Is a Fully Validated CTL Epitope in the CMV pp65 Protein
Human cytomegalovirus (CMV) pp65 (i.e., the 65 kDa lower matrix phosphoprotein) is the major target antigen of CMV-specific cytotoxic T lymphocyte (CTL) responses. Kuzushima et al. reported in Blood in 2001 that, through multiple screening by computer-assisted algorithm prediction, MHC stabilization assays, and enzyme-linked immunospot (ELISPOT) assays, they identified from 83 candidate peptides the dominant CTL epitope QYDPVAALF presented by HLA‑A*24:02 molecules, corresponding to amino acids 341 to 349 of the pp65 protein. Subsequent studies confirmed that the endogenous processing and presentation of this epitope are well defined; in the peripheral blood of healthy donors who are HLA‑A*24 positive and CMV seropositive, CD8⁺ T cells specifically recognizing this peptide account for 0.04% to 0.27% of total CD8⁺ T cells, indicating that in the HLA‑A*24:02 context, the CMV-specific CTL response is highly focused on this pp65 epitope. It is precisely this "response focusing" feature that makes QYDPVAALF an ideal peptide for constructing HLA‑A*24:02 tetramers.
III. Tetramer Technology Enables Direct Quantitative Detection of Antigen-Specific T Cells
Tetramer technology was established by Altman et al. in 1996, and its core idea is to introduce tetravalent multivalent binding into the antigen recognition step: peptide‑MHC (pMHC) monomers formed by in vitro refolding are biotinylated at the BirA substrate peptide site and then combined with fluorophore-conjugated streptavidin at a molar ratio of 4:1 to form tetramers carrying four pMHC complexes. Because the affinity between a single pMHC and the T-cell receptor (TCR) is low and dissociation is rapid, the multivalent binding of tetramers significantly enhances the affinity and stability of binding to specific TCRs, thereby enabling direct staining, counting, and phenotypic analysis of live antigen-specific T cells in flow cytometric analysis. This technique requires no in vitro culture expansion and can directly detect freshly isolated peripheral blood mononuclear cells (PBMCs), making it a classic method for quantifying the frequency of antigen-specific CD8⁺ T cells. Tetramers labeled with allophycocyanin (APC) offer advantages such as high fluorescence quantum yield, good photostability, and low interference from cellular autofluorescence, making them particularly suitable for multicolor flow analysis protocols.
IV. HLA‑A*24:02 Tetramers Have Important Application Value in Both Basic Research and Clinical Immune Monitoring
At the basic research level, HLA‑A*24:02/QYDPVAALF tetramers can be used to analyze the frequency, phenotypic differentiation status, and functional characteristics of CMV-specific CD8⁺ T cells. Domestic researchers have systematically optimized the expression of the HLA‑A*24:02 heavy chain in Escherichia coli and the in vitro refolding system, successfully preparing tetramers loaded with the QYDPVAALF peptide; the tetramer-positive CTLs detected accounted for 0.09% to 0.37% of CD8⁺ T cells, validating the applicability of this reagent for CMV immunology research in the Chinese population. At the clinical and translational level, Japanese scholars used HLA‑A*24:02 tetramers to stain peptide-stimulated CTL lines and found that the frequency of tetramer-positive cells was significantly correlated with the amount of interferon‑γ (IFN‑γ) produced (r = 0.943, P < 0.001), suggesting that tetramer staining can serve as a reliable surrogate indicator of T-cell function. For immunocompromised patients such as those undergoing hematopoietic stem cell transplantation and solid organ transplantation, CMV reactivation is an important complication threatening graft survival; dynamic monitoring of changes in the frequency of CMV-specific CTLs in peripheral blood can provide key laboratory evidence for assessing infection risk, determining the timing of intervention, and evaluating immune reconstitution after adoptive CTL infusion.
Conclusion
Through the molecular construction approach of "peptide‑HLA‑A*24:02 monomer—biotinylation—streptavidin tetramerization," HLA‑A*24:02 tetramers transform antigen-specific T cells, which could previously only be indirectly inferred through functional assays, into a target population that can be directly gated, counted, and typed on flow cytometry plots; and QYDPVAALF, a dominant epitope derived from amino acids 341 to 349 of CMV pp65, gives this tetramer clear biological specificity in HLA‑A*24:02-positive populations——from epitope identification and tetramer validation to quantitative correlation with IFN‑γ secretion, a complete chain of evidence has been formed. Around this tool, UA BIOSCIENCE offers the UA‑MHC HLA‑A24:02/QYDPVAALF CMV pp65 Tetramer‑APC Labelled, providing reliable support for quantitative monitoring of CMV-specific CD8⁺ T-cell immunity, assessment of post-transplant immune reconstitution, and adoptive cell therapy research, and will continue to facilitate innovative exploration in the fields of infection immunology and cellular immunotherapy.
Product Information






